Psoriasis Treatment Market Research Report Information By Drug Class (Tumor Necrosis Factor (TNF) Inhibitors {Adalimumab, Infliximab, Etanercept}, Anticholinergics {Ustekinumab, SecU.K.Inumab, Ixekizumab, Brodalumab}, Vitamin D Analogues {Calcitriol, Calcipotriol, Tacalcitol }), Treatment Type By Topicals ({Over-The-Counter (OTC) Topicals, Topical Non-Steroids, Topical Steroids}, Systemic {Retinoid, Cyclosporine, Methotrexate}, Biologics {Tumor Necrosis Factor Alpha (TNF-Α) Inhibitors, InterleU.K.In 12 And 23 (IL-12/23) Inhibitors, Interle

Psoriasis Treatment Market Overview

The psoriasis treatment market size was valued at USD 14.25 billion in 2021 and is projected to grow from USD 16.45 billion in 2022 to USD 56.16 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2023 - 2032). Increasing number of patients of psoriasis and increasing prevalence of skin disorders in the developed nations are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In November 2023, Lord’s Mark Biotech subsidiary of Lord’s Mark Industries launched Tinefcon, a proprietary medicine for the treatment of Psoriasis. An exclusive agreement has been signed between INVEX Health and Lord’s Mark Biotech (the exclusive distributor) on the product patented by Piramal Life Sciences out of India. Tinefcon is released as a comprehensive remedy for Psoriasis in four forms: tablet, cream, shower gel, and scalp wash, priced at Rs 799 - Rs 3900. In accordance with this new plan, the company started to mentor workers nationally through its scientific sales force, which was exclusively created for Tinefcon since it is aimed at providing a remedy to Psoriasis.

In January 2022, UCB, a worldwide biopharmaceutical company, reported that BIMZELX® (bimekizumab) had received marketing authorization from the Japanese Ministry of Health, Labor and Welfare (MHLW) in patients having plaque psoriasis, pustular Psoriasis generalized and erythroderma psoriatic who have not shown good response by other treatments. Bimekizumab is the first registered therapy for Psoriasis in Japan, designed with high selectivity against two major cytokines associated with inflammatory processes such as interleukin-17F (IL-17F) and interleukin-17A (IL-17A). This makes it the third time Bimzelx has received approval after getting market authorization in EU/EEA nations as well as the UK, where it was approved to treat moderate/severe chronic plaque psoriasis among adults who are candidates for systemic therapy starting in August 2021.

In May 2023, Amgen (NASDAQ: AMGN) announced new research that will examine the use of Otezla® (apremilast) in psoriatic arthritis, which includes the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors often increased in those patients with psoriatic disease. These will be presented at the 2023 European Congress of Rheumatology (EULAR), scheduled for May 31-June 3 in Milan, Italy. Rather than X-ray imaging – a method commonly used to assess joint damage due to psoriatic arthritis – MOSAIC employed magnetic resonance imaging (MRI), a more sensitive means of visualizing inflammation that starts early on and persists throughout joint as well as ethical tissues involved in tendon and ligament attachment sites to bones. The effect of Otezla on joint inflammation and structural progression in psoriatic arthritis, as measured using MRI, was evaluated by MOSAIC.

Psoriasis Treatment Market Trends

• Growing Usage of Combination Therapies for Psoriasis Treatment Boost the Psoriasis Treatment Market Growth

Combination therapy is the most common way to treat psoriasis. It involves the combination of two drugs to achieve improved therapeutic results for patients who inadequately respond to a single drug. Moreover, combination therapy may reduce safety concerns and cumulative toxicity, as a lower dose of two single agents may offer a better safety and efficacy profile when used in combination. The wide range of combination therapies prescribed may reflect increased attention to individualization of treatment to match patients’ diverse preferences. Currently approved topical treatments include prescription medications such as corticosteroids, vitamin D derivatives, vitamin A derivatives (tazarotene), and anthralin.

The most used combinations are topical steroid plus other topical, multiple topical steroids, topical steroid plus vitamin D analog, and topical steroid plus systemic treatment. The growing adoption of combination therapies is likely to fuel the market of psoriasis treatment in the coming years. The graph that follows illustrates the drugs used at the following doses. These results are from individual clinical trials.

Psoriasis Treatment Market Segment Insights

Psoriasis Treatment Drug Class Insights

The market segments of psoriasis treatment, based on drug class, includes Tumor necrosis factor (TNF) inhibitors that it is further bifurcated into adalimumab, infliximab, and etanercept, then Anticholinergics which is further segmented into Ustekinumab, SecU.K.Inumab, Ixekizumab, Brodalumab, and Vitamin D Analogues is further bifurcated into Calcitriol, Calcipotriol, Tacalcitol. tumor necrosis factor (TNF) inhibitors segment held the majority share in 2021, in respect to the  psoriasis treatment market revenue. This is primarily owing to the decline in prices of branded products resulting from the entry of biosimilar versions and growing prescription volume for the interleukin inhibitors. Additionally, interleukins inhibitors are expected to be the fastest segment owing to the increasing number of research trials being conducted across the globe to evaluate the efficacy of these drugs in the treatment of this disease.

July 2022: Arcutis Biotherapeutics, Inc. received the US Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas in patients 12 years of age or older.

December 2021: Amgen Inc. received US FDA approval for Otezla to be used to treat mild to moderate plaque psoriasis in adults. These factors have helped the company to expand its product line in the oral route of administration.

August 2021: UCB S.A. received approval from the European Commission for Bimzelx to treat moderate to severe plaque psoriasis at a recommended dose of 320mg, administered by two subcutaneous injections.

Psoriasis Treatment Type Insights

The  Psoriasis Treatment market segmentation, based on treatment type includes topicals which is sub-segmented into Over-The-Counter (OTC) Topicals, Topical Non-Steroids, Topical Steroids, then systemic further sub-segmented into Retinoid, Cyclosporine, Methotrexate, and then comes biologics which again bi-furcated into Tumor Necrosis Factor Alpha (TNF-Α) Inhibitors, Interle U.K.In 12 And 23 (IL-12/23) Inhibitors, InterleU.K.In 17 (IL-17) Inhibitor, and T Cell Inhibitor. The biologic segment dominated the market share in 2021, in respect to the  psoriasis treatment market revenue. This is due to the several large-scale companies have identified the introduction of new products as an ideal opportunity for market growth. Additionally, market players are focusing on entering into strategic collaborations and mergers, which yielded several innovative products. Therefore, the adoption of psoriasis treatment programs in biologic drugs, which will drive market growth psoriasis treatment during the forecast period.

December 2021: Novartis AG received approval US Food and Drug Administration (FDA) for Cosentyx. It is for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. Also, it is the first biologic indicated for ERA, and the only biologic treatment approved for both ERA and PsA in pediatric patients in the US.

October 2021: Sun Pharmaceutical Industries Ltd. announced that their ILUMYA injections are now available in Canada for the treatment of moderate-to-severe plaque psoriasis.

August 2021: UCB S.A. announced that the European Commission (EC) has granted marketing authorization for BIMZELX (bimekizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Figure 2:  Psoriasis Treatment Market, by Type, 2021 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Psoriasis Treatment Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. North America psoriasis treatment held the largest market share in 2021. This is attributed to the huge number of people suffering with skin disorders, better medical facilities, commercialization of new diagnostic technology, medical policies, and favorable reimbursement policies are factors fueling market growth of psoriasis treatment.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  PSORIASIS TREATMENT MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Psoriasis Treatment market accounts for the second-largest market share due to the increasing prevalence of the disorder across European countries has strongly surged the demand for therapeutic drugs and increasing government initiatives in the region. Furthermore, increasing number of start-ups for psoriasis treatment further drives the growth of the market. For instance, according to the data published by the National Institute for Health and Care Excellence (NICE), the prevalence of the condition was estimated to be around 1.3% to 2.2% among the general population in the UK. Further, the Germany market of psoriasis treatment held the largest market share, and the UK market of psoriasis treatment was the fastest growing market in the European region.

The Asia-Pacific psoriasis treatment market is expected to grow at the significant growth rate during the forecast period. This is due to rising number of government approaches to raise awareness among the population regarding the ill effects of prolonged psoriasis. For instance, in January 2019, the Australian government announced incorporating two new medicines for treatment (Ilumya and Tremfya) in the Pharmaceutical Benefits Scheme (PBS), saving patients up to USD 32,600 per year. Moreover, China market of psoriasis treatment held the largest market share, and the India market of psoriasis treatment was the fastest growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2022–2030.

Psoriasis Treatment Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of psoriasis treatment grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the psoriasis treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the  psoriasis treatment industry to benefit clients and expand the market of psoriasis treatment sector is to manufacture locally to reduce operating costs. In recent years, psoriasis treatment has provided some of the most significant benefits.

Alembic Pharmaceuticals Ltd. is a manufacturer and supplier of generic pharmaceutical products. The company is vertically integrated with the ability to develop, manufacture, and market pharmaceutical products, pharmaceutical substances, and intermediates. It is also the market leader in the Macrolides segment of anti-infective drugs in India. In June 2022, Alembic Pharmaceuticals has received approval from the US health regulator- the US Food & Drug Administration (USFDA), for its development of generic Clobetasol Propionate foam for the treatment of plaque psoriasis.

Clobetasol propionate foam is an effective corticosteroid for treating the scalp with moderate to severe plaque psoriasis. It also offers mild to moderate plaque psoriasis treatment of non-scalp regions, excluding the intertriginous areas and faces of 12 years and older.

Key Companies in the Psoriasis Treatment Market Includes

• Johnson & Johnson Services, Inc. (US)


• Pfizer Inc. (US)


• LEO Pharma A/S (Denmark)


• Novartis AG (Switzerland)


• Merck & Co., Inc. (US)


• UCB S.A. (Belgium)


• AbbVie Inc. (US)


• Sun Pharmaceutical Industries Ltd. (India)


• Eli Lilly and Company (US)


• Amgen Inc. (US)


• Evelo Biosciences, Inc. (US)

Psoriasis Treatment Industry Developments

June 2022: Fosun Pharma and Amgen have together announced a collaboration and license agreement for Fosun Pharma for the commercialization of Amgen’s Otezla and Parsabiv in the Chinese Mainland. The collaboration will enable Amgen to bring the two innovative medicines to Chinese patients with psoriasis and chronic kidney disease more quickly by leveraging Fosun Pharma’s commercial capabilities within China.

November 2022: AbbVie Inc. announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous [IV] induction, and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional or biologic therapy.

December 2021: AbbVie Inc. received the US Food and Drug Administration (FDA) approval for RINVOQ intended to treat adults with active psoriatic arthritis. It can helps to improve joint pain, swelling and stiffness, as well as fatigue, and prevent further joint damage for patients with active PsA.

Psoriasis Treatment Market Segmentation

Psoriasis Treatment Drug Class Outlook

• Tumor Necrosis Factor Inhibitors
  
  
  
  • Adalimumab
  
  
  • Infliximab
  
  
  • Etanercept
  
  
  
  


• Anticholinergics
  
  
  
  • Ustekinumab
  
  
  • K.Inumab
  
  
  • Ixekizumab
  
  
  • Brodalumab
  
  
  
  


• Vitamin D Analogues
  
  
  
  • Calcitriol
  
  
  • Calcipotriol
  
  
  • Tacalcitol
  
  
  
  

Psoriasis Treatment Type Outlook

• Topicals
  
  
  
  • Over The Counter (OTC) Topicals
  
  
  • Topical Non-Steroids
  
  
  • Topical Steroids
  
  
  
  


• Systemic
  
  
  
  • Retinoid
  
  
  • Cyclosporine
  
  
  • Methotrexate
  
  
  
  


• Biologics
  
  
  
  • Tumor Necrosis Factor Alpha (TNF-Α) Inhibitors
  
  
  • K.In 12 And 23 (IL-12/23) Inhibitors
  
  
  • K.In 17 (IL-17) Inhibitor
  
  
  • T Cell Inhibitor
  
  
  
  

Psoriasis Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America